Quantcast
Channel: patent – BioTuesdays
Browsing latest articles
Browse All 13 View Live

Image may be NSFW.
Clik here to view.

Oramed gets patent for oral administration of proteins

The United States Patent and Trademark Office has approved Oramed Pharmaceuticals’ (NASDAQ: ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins.” In a...

View Article



Image may be NSFW.
Clik here to view.

Medifocus receives U.S. patent for heat activated treatment

Medifocus (OTCQX:MDFZF; TSX-V:MFS) has received a new patent from the U.S Patent and Trademark Office, entitled “Apparatus and Method for Pre-Conditioning/Fixation and Treatment of Disease with Heat...

View Article

Image may be NSFW.
Clik here to view.

Medifocus receives two Canadian patents

Medifocus (OTCQX:MDFZF; TSX-V:MFS) has obtained two newly allowed Canadian patents covering its platform technology for the treatment of breast cancer. The titles of the patents are “Thermotherapy...

View Article

Image may be NSFW.
Clik here to view.

Can-Fite gets patent in Japan for CF101

The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine...

View Article

Image may be NSFW.
Clik here to view.

Can-Fite receives patent notice for sexual dysfunction drug

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”. The...

View Article


Image may be NSFW.
Clik here to view.

Revive readies key clinical studies in gout and kidney stones

Revive Therapeutics (TSX-V:RVV; OTCQB:RVVTF) hopes to begin a pivotal Phase 2b clinical trial in mid-year with its Bucillamine drug candidate for the treatment of acute gout flares. Fabio Chianelli “We...

View Article

Image may be NSFW.
Clik here to view.

Leerink starts Depomed at outperform

Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday. “Depomed’s Nucynta for chronic pain provides...

View Article

Image may be NSFW.
Clik here to view.

Oramed gets Indian patent for oral administration of proteins

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to...

View Article


Image may be NSFW.
Clik here to view.

USPTO extends Oramed patent term

The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions...

View Article


Image may be NSFW.
Clik here to view.

Oramed receives patent in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations...

View Article
Browsing latest articles
Browse All 13 View Live




Latest Images